Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the US Food and Drug Administration adverse event reporting system | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the US Food and Drug Administration adverse event reporting system

Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, S. Jones C, Meyer T, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the US Food and Drug Administration adverse event reporting system. Ann Intern Med. 2017;166(11):792-798.

Publication Type:

Journal Article

Authors:

Bersoff-Matcha, Susan J.; Cao, Kelly; Jason, Mihaela; Ajao, Adebola; Jones, S. Christopher; Meyer, Tamra; Brinker, Allen

Source:

Ann Intern Med, Volume 166, Issue 11, p.792-798 (2017)

Keywords:

Adult, Aged, Aged, 80 and over, Antiviral Agents, Chemical and Drug Induced Liver Injury, coinfection, Female, Hepatitis B, Hepatitis B Virus, Hepatitis C, Chronic, Humans, Male, Middle Aged, United States, United States Food and Drug Administration, Virus Activation

Cited On:

Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/28437794

Export Citation:

RIS Format

Top